PaxMedica Inc. Common Sto... (PXMD)
Company Description
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms.
The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis.
It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications.
The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020.
PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
| Country | United States |
| IPO Date | Aug 26, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Howard J. Weisman |
Contact Details
Address: 303 South Broadway Tarrytown, New York United States | |
| Website | https://www.paxmedica.com |
Stock Details
| Ticker Symbol | PXMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001811623 |
| CUSIP Number | 70424C104 |
| ISIN Number | US70424C2035 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Howard J. Weisman | Chief Executive Officer & Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 06, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | NT 10-Q | Filing |
| Oct 03, 2024 | S-1 | Filing |
| Sep 20, 2024 | 10-Q | Quarterly Report |
| Sep 06, 2024 | 8-K | Current Report |
| Aug 14, 2024 | NT 10-Q | Filing |
| Jul 19, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 8-K | Current Report |